ストックスクリーナーアプリを入手
15.64
4.06%
0.61
アフターアワーズ：
15.80
0.16
+1.02%
前日終値:
$15.03
開ける：
$14.99
24時間の取引高:
306.10K
Relative Volume:
0.38
時価総額：
$2.01B
収益：
-
当期純損益:
-
株価収益率:
-7.2562
EPS:
-2.1554
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+8.99%
1か月 パフォーマンス:
+10.06%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$14.56
$15.70
1週間の範囲:
$14.09
$15.70
52週間の値動き範囲:
$11.00
$18.18
Generate Biomedicines Inc Stock (GENB) Company Profile
名前
Generate Biomedicines Inc
セクター
電話
888-469-0055
住所
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
15.64 | 1.94B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2026-03-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-24 | 開始されました | Goldman | Buy |
| 2026-03-24 | 開始されました | Guggenheim | Buy |
| 2026-03-24 | 開始されました | Morgan Stanley | Overweight |
| 2026-03-24 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Generate Biomedicines Inc (GENB) 最新ニュース
Top Generate Biomedicines (GENB) Competitors 2026 - marketbeat.com
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - marketbeat.com
Generate Biomedicines (GENB) Stock Price, News & Analysis - marketbeat.com
Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - marketbeat.com
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com
Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - moomoo.com
Generate Biomedicines: Q2 Earnings Snapshot - marketscreener.com
Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash - TradingView
Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary - TradingView
GENB: Phase 3 clinical and AI-driven pipeline progress offset by rising R&D costs and net loss - TradingView
Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO - Stock Titan
Generate Biomedicines, Inc. (GENB) Return On Assets (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. Revenue Breakdown – NASDAQ:GENB - TradingView
JPMorgan Small Cap Value Portfolio's Generate Biomedicines Inc(GENB) Holding History - GuruFocus
Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted (NASDAQ:GENB) - Seeking Alpha
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
Price to cash flow ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Surges 5.96% – Support and Resistance Levels in FocusVolatility Stop - dars.gov.et
Price to sales forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Consolidates Near Upper Bound as Bulls Test ResistanceRegression Channel - dars.gov.et
Price to earnings forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Number of shareholders of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Edges Lower as Stock Hovers Near Support LevelsDark Pool Volume - dars.gov.et
What Just Happened with Generate Biomedicines' IPO - Kavout | AI
Generate Biomedicines (GENB) Earnings Date and Reports 2026 - MarketBeat
Generate Biomedicines (GENB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Nvidia Invests in Biotech Company Generate Biomedicines - Intellectia AI
Significant Drop for Generate Biomedicines (GENB) as Shares Decl - GuruFocus
Generate Biomedicines Plunges As Rally Suddenly Unwinds - TipRanks
Generate Biomedicines Inc. Q1 2026 Earnings: Pre-revenue Biotech Reports Wider-than-Expected Loss, Stock Slightly DownCore Business Growth - dars.gov.et
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - AOL.com
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday - The Motley Fool
EBITDA of Generate Biomedicines, Inc. – BX:GENB - TradingView
GENBGenerate Biomedicines Inc Dividends - Finviz
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price to book forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to book forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Q&A: Generate Biomedicines CTO talks AI advancements - TechTarget
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Index - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Value Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 3000E Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2500 Value Benchmark - marketscreener.com
Generate Biomedicines Inc (GENB) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):